Cargando…
C-Reactive Protein: Clinical and Epidemiological Perspectives
An important etiopathogenic component of cardiovascular disease is atherosclerosis, with inflammation being an essential event in the pathophysiology of all clinical pictures it comprises. In recent years, several molecules implicated in this process have been studied in order to assess cardiovascul...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932642/ https://www.ncbi.nlm.nih.gov/pubmed/24653858 http://dx.doi.org/10.1155/2014/605810 |
_version_ | 1782304822529097728 |
---|---|
author | Salazar, Juan Martínez, María Sofía Chávez, Mervin Toledo, Alexandra Añez, Roberto Torres, Yaquelín Apruzzese, Vanessa Silva, Carlos Rojas, Joselyn Bermúdez, Valmore |
author_facet | Salazar, Juan Martínez, María Sofía Chávez, Mervin Toledo, Alexandra Añez, Roberto Torres, Yaquelín Apruzzese, Vanessa Silva, Carlos Rojas, Joselyn Bermúdez, Valmore |
author_sort | Salazar, Juan |
collection | PubMed |
description | An important etiopathogenic component of cardiovascular disease is atherosclerosis, with inflammation being an essential event in the pathophysiology of all clinical pictures it comprises. In recent years, several molecules implicated in this process have been studied in order to assess cardiovascular risk in both primary and secondary prevention. C-reactive protein is a plasmatic protein of the pentraxin family and an acute phase reactant, very useful as a general inflammation marker. Currently, it is one of the most profoundly researched molecules in the cardiovascular field, yet its clinical applicability regarding cardiovascular risk remains an object of discussion, considered by some as a simple marker and by others as a true risk factor. In this sense, numerous studies propose its utilization as a predictor of cardiovascular risk through the use of high-sensitivity quantification methods for the detection of values <1 mg/L, following strict international guidelines. Increasing interest in these clinical findings has led to the creation of modified score systems including C-reactive protein concentrations, in order to enhance risk scores commonly used in clinical practice and offer improved care to patients with cardiovascular disease, which remains the first cause of mortality at the worldwide, national, and regional scenarios. |
format | Online Article Text |
id | pubmed-3932642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39326422014-03-20 C-Reactive Protein: Clinical and Epidemiological Perspectives Salazar, Juan Martínez, María Sofía Chávez, Mervin Toledo, Alexandra Añez, Roberto Torres, Yaquelín Apruzzese, Vanessa Silva, Carlos Rojas, Joselyn Bermúdez, Valmore Cardiol Res Pract Review Article An important etiopathogenic component of cardiovascular disease is atherosclerosis, with inflammation being an essential event in the pathophysiology of all clinical pictures it comprises. In recent years, several molecules implicated in this process have been studied in order to assess cardiovascular risk in both primary and secondary prevention. C-reactive protein is a plasmatic protein of the pentraxin family and an acute phase reactant, very useful as a general inflammation marker. Currently, it is one of the most profoundly researched molecules in the cardiovascular field, yet its clinical applicability regarding cardiovascular risk remains an object of discussion, considered by some as a simple marker and by others as a true risk factor. In this sense, numerous studies propose its utilization as a predictor of cardiovascular risk through the use of high-sensitivity quantification methods for the detection of values <1 mg/L, following strict international guidelines. Increasing interest in these clinical findings has led to the creation of modified score systems including C-reactive protein concentrations, in order to enhance risk scores commonly used in clinical practice and offer improved care to patients with cardiovascular disease, which remains the first cause of mortality at the worldwide, national, and regional scenarios. Hindawi Publishing Corporation 2014 2014-02-06 /pmc/articles/PMC3932642/ /pubmed/24653858 http://dx.doi.org/10.1155/2014/605810 Text en Copyright © 2014 Juan Salazar et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Salazar, Juan Martínez, María Sofía Chávez, Mervin Toledo, Alexandra Añez, Roberto Torres, Yaquelín Apruzzese, Vanessa Silva, Carlos Rojas, Joselyn Bermúdez, Valmore C-Reactive Protein: Clinical and Epidemiological Perspectives |
title | C-Reactive Protein: Clinical and Epidemiological Perspectives |
title_full | C-Reactive Protein: Clinical and Epidemiological Perspectives |
title_fullStr | C-Reactive Protein: Clinical and Epidemiological Perspectives |
title_full_unstemmed | C-Reactive Protein: Clinical and Epidemiological Perspectives |
title_short | C-Reactive Protein: Clinical and Epidemiological Perspectives |
title_sort | c-reactive protein: clinical and epidemiological perspectives |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932642/ https://www.ncbi.nlm.nih.gov/pubmed/24653858 http://dx.doi.org/10.1155/2014/605810 |
work_keys_str_mv | AT salazarjuan creactiveproteinclinicalandepidemiologicalperspectives AT martinezmariasofia creactiveproteinclinicalandepidemiologicalperspectives AT chavezmervin creactiveproteinclinicalandepidemiologicalperspectives AT toledoalexandra creactiveproteinclinicalandepidemiologicalperspectives AT anezroberto creactiveproteinclinicalandepidemiologicalperspectives AT torresyaquelin creactiveproteinclinicalandepidemiologicalperspectives AT apruzzesevanessa creactiveproteinclinicalandepidemiologicalperspectives AT silvacarlos creactiveproteinclinicalandepidemiologicalperspectives AT rojasjoselyn creactiveproteinclinicalandepidemiologicalperspectives AT bermudezvalmore creactiveproteinclinicalandepidemiologicalperspectives |